摘要
恶性胸膜间皮瘤(MPM)是一种缺乏治疗选择的致命性疾病,新的靶向药物的临床前研究是必要的。因为以前的研究报道了在大多数的MPM病例中的微管网络中的高的c-Met表达和变化,我们对tivantinib的活性进行了评价,tivantinib最近被发现具有影响除了抑制c-Met以外的微管聚合。在四种MPM细胞系中,tivantinib抑制c-Met活性和微管聚合,导致抑制细胞生长在IC50s介于0.3 µM (MSTO-211H)和 2.4 µM (H2052)之间。此外,由蛋白标记试剂盒B试验和流式细胞术检测到tivantinib协同地增强培美曲塞的抗恶性细胞增生活性和凋亡活性。协同交互作用与减少胸苷酸合成酶表达和抑制迁移活性相关。总的来说,这些数据显示了tivantinib特别的MPM细胞的靶向关键通路活性和与培美曲塞的协同相互作用,这支持进一步的临床方法的研究。
关键词: c-Met,恶性胸膜间皮瘤,转移,培美曲塞,协同交互作用,tivantinib,微管蛋白
Current Drug Targets
Title:Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
Volume: 15 Issue: 14
Author(s): Leticia G. Leon, Maria Gemelli, Rocco Sciarrillo, Amir Avan, Niccola Funel and Elisa Giovannetti
Affiliation:
关键词: c-Met,恶性胸膜间皮瘤,转移,培美曲塞,协同交互作用,tivantinib,微管蛋白
摘要: Malignant pleural mesothelioma (MPM) is a lethal disease with scarce therapeutic options, and preclinical studies on new targeted-agents are warranted. Because previous studies reported high c-Met expression and alterations in the microtubules network in most MPM samples, we evaluated the activity of tivantinib, which has been recently suggested to affect microtubule polymerization in addition to inhibiting c-Met. In four MPM cell lines tivantinib inhibited both c-Met activity and microtubule polymerization, resulting in inhibition of cell-growth with IC50s ranging between 0.3 µM (MSTO-211H) and 2.4 µM (H2052). Furthermore tivantinib synergistically enhanced the antiproliferative and proapoptotic activity of pemetrexed, as detected by sulforhodamine-B-assay and flow cytometry. The synergistic interaction was associated with reduction of thymidylate synthase expression and inhibition of migratory activity. In aggregate, these data show the ability of tivantinib to specifically target key pathways in MPM cells and synergistically interact with pemetrexed, supporting further studies on this therapeutic approach.
Export Options
About this article
Cite this article as:
Leticia G. Leon, Maria Gemelli, Rocco Sciarrillo, Amir Avan, Niccola Funel and Elisa Giovannetti , Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells, Current Drug Targets 2014; 15 (14) . https://dx.doi.org/10.2174/1389450116666141205160924
DOI https://dx.doi.org/10.2174/1389450116666141205160924 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immune Responses to Adenovirus and Adeno-Associated Vectors Used for Gene Therapy of Brain Diseases: The Role of Immunological Synapses in Understanding the Cell Biology of Neuroimmune Interactions
Current Gene Therapy Tip60: Main Functions and Its Inhibitors
Mini-Reviews in Medicinal Chemistry Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Epigenetic Regulation of Gene Expression as an Anticancer Drug Target
Current Cancer Drug Targets Antibody-Onconase Conjugates: Cytotoxicity and Intracellular Routing
Current Pharmaceutical Biotechnology TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Incidental Extracardiac Findings on Coronary Computed Tomography Angiography: A Pictorial Review of Imaging Findings
Current Medical Imaging Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?
Current Medicinal Chemistry New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons
Anti-Cancer Agents in Medicinal Chemistry Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development
Current Pharmaceutical Design Design of Cytotoxic Ribonucleases by Cationization to Enhance Intracellular Protein Delivery
Current Pharmaceutical Biotechnology Lung Cancer: Are we up to the Challenge?
Current Genomics Current Targeting Strategies for Adenovirus Vectors in Cancer Gene Therapy
Current Cancer Drug Targets Predictive Markers for Haematological Toxicity of Pemetrexed
Current Drug Targets Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Major Highlights of the CAR-TCR Summit, Boston, 2016
Anti-Cancer Agents in Medicinal Chemistry Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Current Pharmaceutical Design